Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Prospects for a potential merger between health insurers Cigna Group and Humana Inc. hinge on the upcoming US presidential ...

Leerink Partners analysts are forecasting annual sales of $866 million in 2026, compared to a consensus of $362 million. The ...

On Friday, Accolade Inc (ACCD) stock saw a decline, ending the day at $3.5 which represents a decrease of $-0.08 or -2.23% from the prior close of $3.58. The stock opened at $3.59 and touched a low of ...

On Friday, Aquestive Therapeutics Inc (AQST) stock saw a modest uptick, ending the day at $5.03 which represents a slight increase of $0.11 or 2.24% from the prior close of $4.92. The stock opened at ...

Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...